Immune Design (IMDZ) PT Set at $8.00 by HC Wainwright
HC Wainwright set a $8.00 target price on Immune Design (NASDAQ:IMDZ) in a report issued on Friday, The Fly reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Immune Design from a hold rating to a buy rating and set a $5.00 target price for the company in a report on Tuesday, June 19th. Leerink Swann cut shares of Immune Design from an outperform rating to a market perform rating in a report on Friday. Finally, Royal Bank of Canada reaffirmed an outperform rating and issued a $11.00 target price on shares of Immune Design in a report on Friday. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $8.40.
IMDZ traded down $0.94 on Friday, reaching $1.85. The company had a trading volume of 3,329,086 shares, compared to its average volume of 342,327. Immune Design has a 1 year low of $1.47 and a 1 year high of $11.05. The stock has a market cap of $166.17 million, a PE ratio of -1.06 and a beta of 1.77.
Large investors have recently made changes to their positions in the company. DRW Securities LLC raised its holdings in shares of Immune Design by 59.2% in the second quarter. DRW Securities LLC now owns 58,900 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 21,900 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Immune Design by 456.7% in the first quarter. Dimensional Fund Advisors LP now owns 192,330 shares of the biotechnology company’s stock valued at $635,000 after buying an additional 157,784 shares during the last quarter. Alps Advisors Inc. purchased a new stake in shares of Immune Design in the second quarter valued at about $318,000. Portolan Capital Management LLC purchased a new stake in shares of Immune Design in the second quarter valued at about $2,024,000. Finally, BlackRock Inc. raised its holdings in shares of Immune Design by 2.6% in the first quarter. BlackRock Inc. now owns 1,917,100 shares of the biotechnology company’s stock valued at $6,326,000 after buying an additional 49,022 shares during the last quarter. 49.41% of the stock is owned by institutional investors and hedge funds.
About Immune Design
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
Featured Article: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.